‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

(2013) A. López-Ferrer et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2013) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

(2013) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term safety of ustekinumab for psoriasis

(2013) Neal Kumar et al.   Expert Opinion On Drug Safety

Drug survival rates in patients with psoriasis after treatment with biologics

(2013) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update

(2012) Alexander Nast et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Dermatology Life Quality Index (DLQI): A Paradigm Shift to Patient-Centered Outcomes

(2012) Andrew Y. Finlay et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

(2012) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

(2011) A.M.G. Brunasso et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

(2011) Atsuyuki IGARASHI et al.   JOURNAL OF DERMATOLOGY

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

(2011) David M. Pariser et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE

(2011) J.-P. Ortonne et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab

(2011) Jacqueline M Benson et al.   NATURE BIOTECHNOLOGY

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: Results from the nationwide Danish DANBIO registry

(2010) Bente Glintborg et al.   ARTHRITIS AND RHEUMATISM

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept

(2010) Robert Bissonnette et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

(2010) A. Clemmensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Adalimumab treats psoriasis in patients previously treated with etanercept: A case series

(2009) Paul S. Yamauchi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation

(2009) CL Martyn-Simmons et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Sustained Efficacy and Safety of Adalimumab in Psoriasis Treatment: A Retrospective Study of 49 Patients With and Without a History of TNF-α Antagonist Treatment

(2008) Livia Van et al.   ARCHIVES OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY